CraniUS™ Awarded Competitive $1 Million Grant from the State of Maryland’s Build Our Future Innovation Infrastructure Program
26 Junio 2024 - 8:26AM
Business Wire
Funds will be used to advance CraniUS™’s
transformative, skull-embedded technology designed to transform
brain disease treatment by bypassing the blood-brain barrier.
CraniUS™, an R&D company focused on groundbreaking
diagnostics and treatments for patients with chronic brain disease,
has been awarded a competitive $1 million grant from the State of
Maryland as part of Governor Wes Moore’s Build Our Future
Innovation Infrastructure Pilot Program. This funding milestone –
the first ever granted by the state program - will help CraniUS™
expand its research capabilities, accelerate product development
into human studies, and enhance its contributions to Maryland’s
innovation ecosystem.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240626221554/en/
CraniUS™’s Disruptive Innovation: The
world’s first smart, refillable, and fully implantable medical
device for direct medicine delivery to the brain. (Graphic:
Business Wire)
Governor Moore officially launched the Build Our Future program,
a $9 million initiative designed to support transformative projects
across Maryland’s strategic industry sectors, in 2023 and announced
the recipients of this first pilot funding round earlier this week.
The program provides matching grants of up to $2 million to
projects that demonstrate a substantial impact on growth and
innovation within the state.
CraniUS™’s groundbreaking work in skull-embedded neurotechnology
aims to revolutionize treatments for neurological disorders by
pioneering a new frontier: the brain-medicine interface (BMI),
creating an expansive new platform in neurological medicines that
can be delivered safely and directly to the brain to treat multiple
diseases. Its patented flagship device, the NeuroPASS™, is being
specifically developed to bypass the challenges presented by the
blood-brain barrier, which has rendered traditional therapeutic
treatments of brain disease ineffective.
"We are thrilled and grateful to receive this support from the
State of Maryland," said Mike Maglin, CEO of CraniUS™. "This grant
is not just a recognition of our groundbreaking work, but a
testament to the state’s commitment to fostering innovation and
supporting high-impact projects. With this funding, we are poised
to make significant strides in our mission to develop life-changing
neurotechnology solutions."
About CraniUS™
CraniUS™ was founded May 2021 in Baltimore, MD, as a byproduct
of the emerging field known as "Neuroplastic and Reconstructive
Surgery", through the vision, insight, and pioneering work of Dr.
Chad Gordon. CraniUS™ has raised over $24M to date, been issued 7
patents, and is currently in the midst of a Series B raise.
The NeuroPASS™ device is currently in the pre-clinical
development stage and is not yet commercially available. It is on
the pathway to clinical studies, and any information provided is
subject to change as research progresses.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240626221554/en/
CraniUS™ Media Relations 1(833) 4-CraniUS info@craniusmed.com
https://craniusmed.com